Equities Analysts Offer Predictions for Aemetis, Inc.’s FY2023 Earnings (NASDAQ:AMTX)

Aemetis, Inc. (NASDAQ:AMTX) – Stock analysts at Truist Securiti lifted their FY2023 earnings per share estimates for shares of Aemetis in a research report issued on Wednesday, April 7th. Truist Securiti analyst J. Levy now forecasts that the specialty chemicals company will post earnings per share of $0.89 for the year, up from their prior forecast of $0.80. Truist Securiti also issued estimates for Aemetis’ FY2024 earnings at $3.68 EPS and FY2025 earnings at $6.54 EPS.

Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Aemetis from a “hold” rating to a “sell” rating in a research note on Tuesday, March 16th. Truist Securities started coverage on Aemetis in a research note on Thursday, March 25th. They issued a “buy” rating and a $35.00 target price for the company. Truist started coverage on Aemetis in a research note on Friday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. Credit Suisse Group started coverage on Aemetis in a research note on Monday, March 29th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, HC Wainwright increased their target price on Aemetis from $15.00 to $28.00 in a research note on Monday, March 15th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $31.60.

Shares of NASDAQ:AMTX opened at $24.70 on Thursday. The firm has a market capitalization of $669.35 million, a PE ratio of -17.64 and a beta of 0.09. The business has a 50-day moving average of $17.30 and a two-hundred day moving average of $7.12. Aemetis has a 12 month low of $0.53 and a 12 month high of $27.44.

Aemetis (NASDAQ:AMTX) last released its earnings results on Monday, March 15th. The specialty chemicals company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.10). The company had revenue of $37.33 million during the quarter, compared to analysts’ expectations of $47.34 million.

A number of hedge funds and other institutional investors have recently modified their holdings of AMTX. Renaissance Technologies LLC grew its stake in Aemetis by 57.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,731,349 shares of the specialty chemicals company’s stock valued at $4,311,000 after purchasing an additional 629,721 shares in the last quarter. Virtu Financial LLC grew its stake in Aemetis by 389.3% during the 4th quarter. Virtu Financial LLC now owns 130,116 shares of the specialty chemicals company’s stock valued at $324,000 after purchasing an additional 103,522 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Aemetis during the 4th quarter valued at approximately $76,000. Finally, HighPoint Advisor Group LLC acquired a new stake in Aemetis during the 4th quarter valued at approximately $197,000. Hedge funds and other institutional investors own 12.89% of the company’s stock.

About Aemetis

Aemetis, Inc operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products primarily through the conversion of ethanol and biodiesel plants into advanced bio refineries.

See Also: What are high-yield dividend stocks?

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.